Treating Infant Respiratory Distress Disorders with Pulmonary Surfactants

FOR IMMEDIATE RELEASE
New York, U.S.:Infants who experience respiratory distress disorders are commonly treated with pulmonary surfactants. Respiratory distress syndrome (RDS) is a condition in which the lungs are not fully developed and the infant has trouble breathing on his or her own. This is due to insufficient amounts of surfactant, which is a naturally occurring substance that coats the lungs and allows them to function properly. Infants who are born prematurely – approximately six weeks before their due date – sometimes do not have enough natural surfactant to breathe properly.

Without sufficient amounts of pulmonary surfactant, an infant's lungs might collapse. This means infants with respiratory distress disorders may not get enough oxygen to support organ function. Respiratory distress disorder is apparent at birth, or directly following birth. Symptoms can include flaring the nostrils, grunting, or rapid, shallow breathing.

Respiratory Distress Disorder Treatment Options
An infant who experiences respiratory distress disorders due to insufficient pulmonary surfactant should be treated as soon as RDS is diagnosed. This typically will happen directly after birth. Infants with RDS need specialized care in a neonatal intensive care unit (NICU). Babies in the NICU receive care from doctors and nurses who specialize in treating infant respiratory distress disorders, among others.

Once in the NICU, infants need immediate help with their breathing. This can be achieved through a variety of different treatments and therapies. For example, an infant with respiratory distress might receive pulmonary surfactant replacement therapy, which involves administering medication. Curosurf, Infasurf, and Survanta are common artificial pulmonary surfactants that treat infant respiratory distress disorders. These surfactants are administered until the infant is able to produce surfactant on his or her own, and the lungs become more developed. Artificial pulmonary surfactants are typically administered through a tube that sends the medication directly into the infant’s lungs.

Pulmonary surfactant therapy should only be administered by medical professionals within the confines of an NICU. Infants with RDS will usually receive pulmonary surfactant therapy several times a day for a few days, or until lung function improves.

Another treatment option for infants with respiratory distress disorders it to receive breathing support from a mechanical ventilator or a nasal continuous positive airway pressure machine (NCPAP). This machine gently moves air into the lungs through prongs placed in the baby’s nostrils.

For further enquires related to ONY, Inc. and Infasurf, please free to email at info@onyinc.com or visit www.infasurf.com now.

ONY, Inc. of Amherst, New York is the owner of Infasurf (calfactant). Infasurf is derived from natural surfactants to offer relief from this syndrome.

ONY, Inc.
1576 Sweet Home Rd.
Amherst, NY 14228
Tel: (716) 636-9096
Toll-free: (877) 274-4469
info@onyinc.com
http://www.infasurf.com/
Monday to Friday, 9 a.m. to 5 p.m. Eastern, excluding holidays

This release was published on openPR.